For the quarter ending 2026-03-31, BEAM made $31,738K in revenue. -$96,499K in net income. Net profit margin of -304.05%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| License and collaboration revenue | 31,738 | 114,109 | 9,698 | 8,466 |
| Research and development | 104,524 | 99,275 | 109,769 | 101,758 |
| General and administrative | 34,429 | 32,279 | 26,740 | 26,859 |
| Total operating expenses | 138,953 | 131,554 | 136,509 | 128,617 |
| Loss from operations | -107,215 | -17,445 | -126,811 | -120,151 |
| Change in fair value of derivative liabilities | 2,500 | 50 | -2,757 | 1,147 |
| Change in fair value of non-controlling equity investments | 16 | -3,329 | 4,937 | 4,415 |
| Change in fair value of contingent consideration liabilities | -514 | 765 | -1,000 | 28 |
| Gain on sale of equity method investment | - | 255,146 | - | - |
| Interest and other income (expense), net | 9,867 | 10,640 | 10,903 | 12,326 |
| Total other income (expense) | 12,897 | 261,742 | 14,083 | 17,860 |
| Net gain before income taxes | - | 244,297 | -112,728 | -102,291 |
| Net gain | -94,318 | 244,297 | -112,728 | -102,291 |
| Unrealized gain (loss) on marketable securities | -2,181 | 321 | 780 | -150 |
| Comprehensive gain | -96,499 | 244,618 | -111,948 | -102,441 |
| Basic EPS | -0.91 | 2.373 | -1.1 | -1 |
| Diluted EPS | -0.91 | 2.373 | -1.1 | -1 |
| Basic Average Shares | 103,262,001 | 103,081,012 | 102,570,801 | 101,995,184 |
| Diluted Average Shares | 103,262,001 | 103,081,012 | 102,570,801 | 101,995,184 |
Beam Therapeutics Inc. (BEAM)
Beam Therapeutics Inc. (BEAM)